报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

1～2月，受到传统节日等因素影响，医药行业整体发展增速尚未明显回升。其中，医药制造业投资完成额同比增长21.2%，比上年同期下降12.8个百分点；中成药产量同比增长5.3%，增速同比放缓6.61个百分点。值得注意的是，化学原料药产量快速增长。1～2月，我国化学原料药产量同比增长28.2%，增速同比提高15.01个百分点。然而，出口依然低迷。2月医药品出口额同比下降9.4%，环比下降34.4%。2014年是药品招标大年，随着各地药品招标的稳步推进，医药行业发展增速有望逐步回升，产销规模有望稳步上升。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

《中国经济时报》报道，国家卫计委等部门4月4日联合下发了《关于推进县级公立医院综合改革的意见》（下称《意见》），此次《意见》要求各地应按照2014年县级公立医院综合改革试点覆盖50%以上的县（市），2015年全面推开的时间节点，制定县级公立医院综合改革任务具体分工方案。

Hypertension, also referred to as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Changing lifestyle habits such as poor diet, lack of exercises, and smoking are the major causes of hypertension. Hypertension leads to the damage of organs and can cause several illnesses such as renal failure, aneurysms, heart failure, strokes, and heart attacks. There are two major types of hypertension: primary or essential hypertension and secondary hypertension. The Global Hypertension Drugs market is currently growing at a slow rate and is expected to post a CAGR of 1.20 percent during the forecast period. In 2013, the Americas dominated the market and is expected to continue its dominance during the forecast period. The US was the major revenue contributor to the market in the Americas. The Americas was followed by the EMEA and APAC regions. There is a vast opportunity for vendors in this market to expand into the APAC region.

A therapeutic vaccine is a biological combination developed to improve immunity by inducing an attack against a diseased cell or tissue. This kind of vaccine differs from the prophylactic vaccine, which is administered to a diseased individual to induce a defense mechanism. There are two approved therapeutic vaccines namely Provenge and Oncophage. A large number of therapeutic vaccines are under clinical development and are expected to be approved for use during the forecast period. In 2013, a large fraction of the growth of the Global Therapeutic Vaccines market stemmed from the Americas, which accounted for 90 percent of the market. The EMEA region accounted for less than 10 percent of the market. While it is expected that the revenue from the APAC region will grow exponentially during the forecast period, owing to increased acceptance of therapeutic vaccines; there are no such approved products in this region currently. The market is expected to grow at a CAGR of 62.81 percent during the forecast period.

Companion diagnostic tests are used to identify suitable patients for administering specific drugs and monitoring the prognosis of drug effects on the disease. This concept of combining a drug with a diagnostic test is known as predictive medicine or personalized medicine. A companion diagnostic test has the ability to predict the risks of the disease and monitor its therapeutic response. The tests enable physicians to make decisions on the type of drugs and dosage administration and thereby reduce the mortality rates associated with diseases such as cancer and neurodegenerative disorders. The demand for companion diagnostic tests is expected to grow at a significant rate during the forecast period. In 2013, the Americas dominated the Global Companion Diagnostics market and it was followed by the EMEA region. Together, these two regions accounted for 90 percent of the market revenue. However, the APAC region is expected to grow at the fastest rate during the forecast period because of the increase in the incidence of infectious diseases, the demand for targeted therapeutics, and the increased adoption of diagnostic products. The Global Companion Diagnostics market is expected to grow at a CAGR of 18.59 percent during the forecast period.

DN is a disease that affects the kidney glomeruli. The disease is caused by high blood sugar or hyperglycemia. When diabetes damages the kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the blood, it results in DN, also called diabetic kidney disease.The Global Diabetic Nephropathy market is expected to witness slow growth during the period 2013-2018. In 2013, the market was dominated by the Americas, where the major contribution was from the US, and this trend is expected to continue during the forecast period. The Americas was followed by the EMEA and APAC regions. There is a vast opportunity for vendors in this market to expand into the APAC region. The market is expected to witness an improvement in its growth rate and post a CAGR of 5.19 percent during the forecast period.

In vitro toxicity testing is the analysis of the adverse effects of toxic chemical or biological substances on cultured cells. All pharmaceutical, chemical, cosmetic, and food products have to undergo rigorous toxicity testing before they are marketed to ensure safe usage. Toxicity tests are conducted to examine the effect of the product or ingredients on organs or body systems. In vitro toxicity testing uses yeast, bacterial, mammalian or human cell cultures, tissue slices, and subcultures for testing for toxicity, ocular irritation, and skin corrosion/irritation. The Global In Vitro Toxicity Testing market is growing at a rapid rate and is expected to post a CAGR of 15.84 percent during the period 2013-2018. In 2013, the Americas led the market, followed by the EMEA and APAC regions. The emergence of sophisticated technologies in molecular and cellular biology has encouraged a rapid evolution in life sciences and toxicology. In 2013, the Cosmetic industry accounted for the largest share in the market. However, other end-user segments such as the Pharmaceutical and Food industries are also expected to make significant contributions to the overall market revenue in the near future.

Nutraceuticals are products that provide pharmacological and medicinal benefits, in addition to providing nutrition. Nutraceutical ingredients are key functional ingredients of nutraceutical products. These ingredients may be natural bioactive substances or chemical compounds, which help prevent diseases and improve heath. The Global Nutraceutical Ingredients market is expected to witness steady growth with a CAGR of 7.03 percent during the forecast period. In 2013, the APAC region dominated the market, owing to an increase in demand for nutraceutical products from countries such as Japan, China, South Korea, and India. This region was followed by Europe and North America.

Pain management is a branch of medicine that uses an interdisciplinary approach for reducing pain and improving the quality of life. This approach can be simple or complex, depending on the cause of the pain. Pain management requires special skills and techniques such as interventional procedures, psychological counseling and support, and acupuncture and other alternative therapies. The Global Pain Management Drugs market is growing at a steady rate, especially in developed countries, and is expected to grow at a CAGR of 3.83 percent during the forecast period. Over the last few years, the market has been witnessing new developments and innovations in pain management drugs. In 2013, the Americas generated the highest revenue in the market, followed by the EMEA and APAC regions.

本刊以七大战略性新兴产业——节能环保、新一代信息技术、生物、高端装备制造、新能源、新材料、新能源汽车为研究重点，关注国家高层和各部委的动态，剖析国家和地方的新兴产业政策。本刊设有政策导读、领导讲话、七大战略性新兴产业本周国内外行业动态和重点企业新闻、投资专题四大板块，能够实时监测新兴产业和重点企业动态，把握新兴产业发展方向，研究发展重点，寻求发展机遇。